3 completed, 2 recruiting, 2 terminated. 7 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 3, Recruiting 2, Terminated 2 |
| Phase 3 | 3 | Completed 1, Recruiting 1, Terminated 1 |
Follow ozanimod: new trials by email Literature Review of ozanimod trials Research Report on ozanimod
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ozanimod in Patients With Alzheimer's Disease Ozanimod, Conventional medication - Alzheimer Disease | Phase 2 | Recruiting | ChenXiaoChun | 40 | 2025-08-13 | 2026-07-27 |
| A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pediatric Participants With Moderately to Severely Active Crohn's Disease With an Inadequate Response to Conventional Therapy Ozanimod - Crohn Disease | Phase 2 / Phase 3 | Terminated | Bristol-Myers Squibb | 5 | 2023-08-22 | 2025-04-22 |
| A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis Ozanimod - Colitis, Ulcerative | Phase 2 / Phase 3 | Recruiting | Bristol-Myers Squibb | 120 | 2022-05-30 | 2026-10-20 |
| COVID-19 Ozanimod Intervention Study Ozanimod, Standard of care - COVID-19 | Phase 2 | Terminated | Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec | 43 | 2020-09-16 | 2024-02-20 |
| Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease RPC1063 - Crohn's Disease | Phase 2 | Completed | Celgene | 69 | 2015-10-09 | 2021-01-22 |
| Efficacy and Safety Study of Ozanimod in Ulcerative Colitis Ozanimod, Placebo - Ulcerative Colitis | Phase 2 | Completed | Celgene | 199 | 2012-12-26 | 2021-05-19 |
| Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients Ozanimod, Placebo - Relapsing Multiple Sclerosis | Phase 2 / Phase 3 | Completed | Celgene | 258 | 2012-09-18 | 2021-02-11 |
Colitis, Ulcerative (2) · Crohn Disease (2) · Alzheimer Disease (1) · COVID-19 (1) · Cognitive Dysfunction (1)
Celgene (3) · Bristol-Myers Squibb (2) · Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec (1) · ChenXiaoChun (1)
Canada (5) · Poland (5) · United States (5) · Belgium (4) · Hungary (4) · Australia (3) · Russia (3) · Spain (3) · Ukraine (3) · Bulgaria (2) · France (2) · Germany (2) · Greece (2) · Israel (2) · China (1)
AnnKatrin Petersen, MD (1) · David Marsolais, PhD (1) · Kanthi Kollengode, MD (1) · Pascale Blais-Lecours, PhD (1)
PMID 26879276, PMID 30043658, PMID 32553149, PMID 37898184, PMID 38568396, PMID 39018016, PMID 41677183
2023 (1)